CSI Market
Sign In | Register

Ascendis Pharma A (ASND) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access ASND Annual Income Statement →
The data below summarizes Ascendis Pharma A's income statement results from Dec 31 2024 to Dec 31 2025, enabling period-by-period comparison of operating performance.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
Q4 2025 		0 0 0 (Dec 31 2024)
Revenues
Sales of Products0.00
Total Revenue278.99
Costs & Expenses
Cost of Goods and Services Sold27.08
Gross Profit251.91
Selling, Administration, Marketing512.81
Research and Development Expense340.06
Other Operating Expense / -Income0.00
Total operating costs including COS959.17
Operating income / -loss-152.62
Net Interest (-)Expense / Income0.00
Other loss / -income0.00
Total costs & expenses1,044.72
Income & Taxes
Income / -loss before income taxes-35.15
Income taxes expenses / -benefit7.68
Income after income taxes-255.40
Income / -loss from continuing operations-255.40
Net income / -loss-42.83
Income / -loss to shareholder-39.08
EBIT-35.15
EBITD-15.88
EBITDA-15.33
Earnings Per Share
Basic EPS (excl. extra items)-0.55
Basic Net EPS-0.55
Basic shares outstanding (Mill. of Units)60.61
Diluted Net EPS-0.55
Diluted average shares (Mill. of Units)60.61
4 historic quarters locked

Sign in to unlock the full Ascendis Pharma A income statement history.

Sign In Create Free Account

About ASND Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.